about
Solute Carrier NTCP Regulates Innate Antiviral Immune Responses Targeting Hepatitis C Virus Infection of HepatocytesA novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmissionHepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agentsSynergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C.Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibodyEFTUD2 Is a Novel Innate Immune Regulator Restricting Hepatitis C Virus Infection through the RIG-I/MDA5 Pathway.Hepatitis C Virus Proteins Interact with the Endosomal Sorting Complex Required for Transport (ESCRT) Machinery via Ubiquitination To Facilitate Viral Envelopment.Expression of Interferon Effector Gene SART1 Correlates with Interferon Treatment Response against Hepatitis B Infection.EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapyCD81-receptor associations--impact for hepatitis C virus entry and antiviral therapies.Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects.Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha.The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination.The FGL2/fibroleukin prothrombinase is involved in alveolar macrophage activation in COPD through the MAPK pathway.HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex.Modeling the antiviral activity of ribavirin against hepatitis C virus in cell culture.Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes.A bile acid transporter as a candidate receptor for hepatitis B and D virus entry.Effect of anluohuaxian tablet combined with gamma-IFN on schistosomal liver fibrosis.
P50
Q27928046-AD7E71F0-6411-45FF-9F06-509AF5AFE33EQ28488372-688AB101-A73A-4CF7-91A8-62D907DC7B8EQ28538891-F8C00A2C-2CFF-425C-8B2A-8689F32968F4Q35135565-E945D290-0CEA-4D71-B7BE-34E551BBFDB2Q35602284-B594EE03-4B14-43AC-93DF-FE9B746D56CBQ35602911-04836303-1C31-49C2-8204-25C1513E4811Q37385740-828049F6-26B6-466E-8104-913D4FC50697Q37547706-A47EF066-575C-46D8-A1BA-2C082FB910DBQ37609988-568E2717-5936-4DB5-AA00-7C04960DF508Q37611842-30ED9380-7969-4A02-8D2D-592FF0644BF3Q37730661-DBAB7353-A430-40E9-B0FF-0404F96DE616Q39177270-D869C120-F93A-4F41-B965-BD66EC93AAC4Q39256583-C614F17A-32D8-4B55-BFED-C0A89FA714B7Q39708168-99231CB6-5410-494B-BB5C-397FF831B5C6Q42990165-695C5F5C-E848-487A-9F84-52DF8D1EBFB6Q42992489-594F5DB2-5EA2-4030-A507-610A0B6CAB5BQ42999009-23DB83DA-A436-424E-B4BA-3BF3E2B99F2EQ44414292-7823F2E7-F812-4698-8F39-3CFDA815BF1AQ51815527-FB95B2E9-4EC2-474E-A836-D998A3A5CDDC
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Fei Xiao
@ast
Fei Xiao
@en
Fei Xiao
@es
Fei Xiao
@nl
Fei Xiao
@sl
type
label
Fei Xiao
@ast
Fei Xiao
@en
Fei Xiao
@es
Fei Xiao
@nl
Fei Xiao
@sl
prefLabel
Fei Xiao
@ast
Fei Xiao
@en
Fei Xiao
@es
Fei Xiao
@nl
Fei Xiao
@sl
P1053
E-7133-2013
P106
P1153
55537293000
P31
P3829
P496
0000-0001-7353-2700